Page 30 - நான்காவது எஸ்டேட் வலைப்பின்னல் தேர்வுமுறை ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நான்காவது எஸ்டேட் வலைப்பின்னல் தேர்வுமுறை ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நான்காவது எஸ்டேட் வலைப்பின்னல் தேர்வுமுறை ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Vertex Energy, Inc.: Vertex Energy Reports Fourth Quarter and Full-Year 2020 Results


Vertex Energy, Inc.: Vertex Energy Reports Fourth Quarter and Full-Year 2020 Results
HOUSTON, TX / ACCESSWIRE / March 9, 2021 /
Vertex Energy, Inc. (NASDAQ:VTNR), Vertex Energy or the Company ), a leading specialty refiner and marketer of high-quality hydrocarbon products, today announced its financial results for the fourth quarter and full-year ended December 31, 2020.
FOURTH QUARTER 2020 RESULTS
Myrtle Grove Phase-One start-up completed; Phase-Two of the project has commenced
9% y/y organic growth in direct UMO collections driven by customer account growth
Total cash and available liquidity of $12.3 million as of December 31, 2020
MANAGEMENT OUTLOOK
Anticipate positive free cash flow, net income and Adjusted EBITDA for the full-year 2021 ....

United States , Myrtle Grove , Port Arthur , Benjaminp Cowart , Belle Chasse , Acquisition Of Crystal Energy , Company Heartland , Bunker One United States Inc , Vertex Energy Inc , Exchange Commission , Company Marrero , Paycheck Protection Program , Vertex Energy , Grove Phase One , Free Cash Flow , Belle Chase , Coronavirus Aid , Economic Security Act , Investor Relations , Gulf Coast , Private Securities Litigation Reform Act , Bunker One , Cash Flow , Net Loss , Convertible Preferred , Crystal Energy ,

Evelo Biosciences, Inc.: Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights


(2)
-Announced new positive data in human experimental model of inflammation of EDP1815-
-Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021-
-Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021-
-Up to 8 clinical data readouts expected over next 18 months-
-Management to host conference call at 8:30 a.m. ET-
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the fourth quarter and full year 2020. ....

United Kingdom , Evelo Biosciences , Jessica Cotrone , Jonathan Zung , Johna Hohneker , Kostenloser Wertpapierhandel , John Hohneker , Development Expenses , Evelo Biosciences Inc , Rutgers University , Society For Immunotherapy Of Cancer , Evelo Executive Team , Initiated Phase , Simba Gill , Chief Executive Officer , Chief Development Officer , Full Year , Human Experimental Model , Eczema Area , Severity Index , Global Assessment , Body Surface Area , Atopic Dermatitis , Dermatology Life Quality Index , Patient Oriented Eczema Measure , Anniversary Annual ,

Stabilis Solutions Announces Fourth Quarter and Full Year 2020 Earnings Call

HOUSTON, TX / ACCESSWIRE / March 8, 2021 / Stabilis Solutions, Inc. (OTCQX:SLNG) ("Stabilis"), a leading provider of distributed natural gas ("LNG") and hydrogen fuels, is pleased to announce that it will ....

United States , Andrew Puhala , Stabilis Solutions , Stabilis Solutions Inc , ஒன்றுபட்டது மாநிலங்களில் ,